Lipid Metabolism Profiling and Bladder Cancer

Besiroglu H

DOI: https://doi.org/10.4172/2153-0769.1000154

2015-01-01

Abstract:Lipid Metabolism Profiling and Bladder Cancer, Metabolomics:Open Access.

What problem does this paper attempt to address?

Characterization of the Lipid Metabolism in Bladder Cancer to Guide Clinical Therapy

Yuan-Yuan Yang,Sen-Yuan Hong,Yang Xun,Chen-Qian Liu,Jian-Xuan Sun,Jin-Zhou Xu,Meng-Yao Xu,Ye An,Deng He,Qi-Dong Xia,Shao-Gang Wang

DOI: https://doi.org/10.1155/2022/7679652

IF: 4.501

2022-09-14

Journal of Oncology

Abstract:Background. Bladder cancer is one of the most common malignancies of the urinary system with an unfavorable prognosis. More and more studies have suggested that lipid metabolism could influence the progression and treatment of tumors. However, there are few studies exploring the relationship between lipid metabolism and bladder cancer. This study aimed to explore the roles that lipid metabolism-related genes play in patients with bladder cancer. Methods. TCGA_BLCA cohort and GSE13507 cohort were included in this study, and transcriptional and somatic mutation profiles of 309 lipid metabolism-related genes were analyzed to discover the critical lipid metabolism-related genes in the incurrence and progression of bladder cancer. Furthermore, the TCGA_BLCA cohort was randomly divided into training set and validation set, and the GSE13507 cohort was served as an external independent validation set. We performed the LASSO regression and multivariate Cox regression in training set to develop a prognostic signature and further verified this signature in TCGA_BLCA validation set and GSE13507 external validation set. Finally, we systematically investigated the association between this signature and tumor microenvironment, drug response, and potential functions and then verified the differential expression status of signature genes in the protein level by immunohistochemistry. Results. A novel 6-lipidmetabolism-related gene signature was identified and validated, and this risk score model could predict the prognosis of patients with bladder cancer. In addition, the prognostic model was tightly related to immune cell infiltration and tumor mutation burden. Gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) showed that mTOR signaling pathway, G2M checkpoint, fatty acid metabolism, and hypoxia were enriched in patients in the high-risk score groups. Furthermore, 3 therapies specific for bladder cancer patients in different risk scores were identified. Conclusions. In conclusion, we investigated the lipid metabolism-related genes in bladder cancer through comprehensive bioinformatic analysis. A novel 6-gene signature associated with lipid metabolism for predicting the outcomes of patients with bladder cancer was conducted and validated. Furthermore, the risk score model could be utilized to indicate the choice of therapy in bladder cancer.

oncology
Integrative Analysis of Plasma Metabolomics and Proteomics Reveals the Metabolic Landscape of Breast Cancer

An Rui,Yu Haitao,Wang Yanzhong,Lu Jie,Gao Yuzhen,Xie Xinyou,Zhang Jun

DOI: https://doi.org/10.1186/s40170-022-00289-6

2022-01-01

Cancer & Metabolism

Abstract:BACKGROUND:Breast cancer (BC) is the most commonly diagnosed cancer. Currently, mammography and breast ultrasonography are the main clinical screening methods for BC. Our study aimed to reveal the specific metabolic profiles of BC patients and explore the specific metabolic signatures in human plasma for BC diagnosis.METHODS:This study enrolled 216 participants, including BC patients, benign patients, and healthy controls (HC) and formed two cohorts, one training cohort and one testing cohort. Plasma samples were collected from each participant and subjected to perform nontargeted metabolomics and proteomics. The metabolic signatures for BC diagnosis were identified through machine learning.RESULTS:Metabolomics analysis revealed that BC patients showed a significant change of metabolic profiles compared to HC individuals. The alanine, aspartate and glutamate pathways, glutamine and glutamate metabolic pathways, and arginine biosynthesis pathways were the critical biological metabolic pathways in BC. Proteomics identified 29 upregulated and 2 downregulated proteins in BC. Our integrative analysis found that aspartate aminotransferase (GOT1), L-lactate dehydrogenase B chain (LDHB), glutathione synthetase (GSS), and glutathione peroxidase 3 (GPX3) were closely involved in these metabolic pathways. Support vector machine (SVM) demonstrated a predictive model with 47 metabolites, and this model achieved a high accuracy in BC prediction (AUC = 1). Besides, this panel of metabolites also showed a fairly high predictive power in the testing cohort between BC vs HC (AUC = 0.794), and benign vs HC (AUC = 0.879).CONCLUSIONS:This study uncovered specific changes in the metabolic and proteomic profiling of breast cancer patients and identified a panel of 47 plasma metabolites, including sphingomyelins, glutamate, and cysteine could be potential diagnostic biomarkers for breast cancer.
Metabolomic profiling of human bladder tissue extracts

Krzysztof Ossoliński,Tomasz Ruman,Valérie Copié,Brian P. Tripet,Artur Kołodziej,Aneta Płaza-Altamer,Anna Ossolińska,Tadeusz Ossoliński,Zuzanna Krupa,Joanna Nizioł

DOI: https://doi.org/10.1007/s11306-023-02076-w

2024-01-26

Metabolomics

Abstract:Bladder cancer is a common malignancy affecting the urinary tract and effective biomarkers and for which monitoring therapeutic interventions have yet to be identified.

endocrinology & metabolism
In Silico Establishment and Validation of Novel Lipid Metabolism-Related Gene Signature in Bladder Cancer

Xianchao Sun,Ying Zhang,Yilai Chen,Shiyong Xin,Liang Jin,Xiang Liu,Zhen Zhou,Jiaxin Zhang,Wangli Mei,Bihui Zhang,Xudong Yao,Guosheng Yang,Lin Ye

DOI: https://doi.org/10.1155/2022/3170950

2022-04-18

Abstract:Background: Aberrant lipid metabolism is an alteration common to many types of cancer. Dysregulation of lipid metabolism is considered a major risk factor for bladder cancer. Accordingly, we focused on genes related to lipid metabolism and screened novel markers for predicting the prognosis of bladder cancer. Methods: RNA-seq data for bladder cancer were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The nonnegative matrix factorization (NMF) algorithm was used to classify the molecular subtypes. Weighted correlation network analysis (WGCNA) was applied to identify coexpressed genes, and least absolute shrinkage and selection operator (LASSO) multivariate Cox analysis was used to construct a prognostic risk model. External validation data and in vitro experiments were used to verify the results from in silico analysis. Results: Bladder cancer samples were grouped into two clusters based on the NMF algorithm. A total of 1467 genes involved in coexpression modules were identified in WGCNA. We finally established a 5-gene signature (TM4SF1, KCNK5, FASN, IMPDH1, and KCNJ15) that exhibited good stability across different datasets and was also an independent risk factor for prognosis. Furthermore, the predictive efficacy of our model was generally higher than the predictive efficacy of other published models. Distinct risk groups of patients also showed significantly different immune infiltration cell patterns and associations with clinical variables. Moreover, the 5 signature genes were verified in clinical samples by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry, which were in agreement with the in silico analysis. For in vitro experiments, knockdown of IMPDH1 markedly inhibited cell proliferation in bladder cancer. Conclusion: We established a 5-gene prognosis signature based on lipid metabolism in bladder cancer, which could be an effective prognostic indicator.
Abstract 4765: Tumor, serum and plasma metabolome in patients with high-grade bladder cancer

Maria-Malvina Tsamouri,Akshaya Karthikeyan,Christopher A. Lucchesi,Blythe P. Durbin-Johnson,Marc A. Dall'Era,Paramita M. Ghosh

DOI: https://doi.org/10.1158/1538-7445.am2024-4765

IF: 11.2

2024-03-28

Cancer Research

Abstract:Introduction: Bladder cancer (BlCa) ranks as the sixth most prevalent cancer in the world. A number of urine based BlCa detection tests have recently been approved for clinical use, including the NMP22 tests and the bladder tumor antigen (BTA) tests for both detection and monitoring of patients with known bladder cancer. The FDA have approved them both for surveillance in BlCa only in conjunction with cystoscopy. Unfortunately, the sensitivity and specificity of these tests are poor, and cannot distinguish between aggressive and non-aggressive tumors. This project aims to identify alternate markers that can overcome these drawbacks. Methods: We characterized the global metabolome of 47 bladder tumors retrieved by radical cystectomy (RC) or TURBT, including 14 specimens with matching plasma and serum samples. All specimens were subjected to untargeted metabolomic approaches with gas chromatography- time-of-flight mass spectrometry (GC-TOF MS) to profile primary metabolites, hydrophilic interaction liquid chromatography MS (HILIC-QTOF MS) to profile biogenic amines, and liquid chromatography charged surface hybrid MS (LC-CSH-QTOF MS) to characterize complex lipids. Differentially expressed metabolites were analyzed with respect to grade, stage, metastases, and the use of neoadjuvant chemotherapy. For selected metabolites, area under the ROC curve (AUC) is calculated as % sensitivity vs. 100% specificity. Expression of highly discriminatory metabolites were then validated in the plasma and serum samples to determine which forum would provide greater specificity. Results: We first assembled a discovery cohort of 33 patients who did not have matching blood specimen for primary metabolites, biogenic amines and complex lipids. Comparison of high vs low grade tumors yielded two lipids, a sphingomyelin (SM (d38) and a phosphatidylcholine PC(p-38), that were significantly different (adjusted p-value 2.5). These results were validated in the 14-sample cohort with matching plasma and serum of which the latter showed significant correlation between tumor and plasma (Spearman R=0.872, adj p=0.03). Conclusions: Our results indicate that certain sphingomyelins and phosphatidylcholines may be useful as plasma markers of high grade BlCa. Further analyses are required to evaluate whether these markers are more discriminatory compared to existing urinary markers. Citation Format: Maria-Malvina Tsamouri, Akshaya Karthikeyan, Christopher A. Lucchesi, Blythe P. Durbin-Johnson, Marc A. Dall'Era, Paramita M. Ghosh. Tumor, serum and plasma metabolome in patients with high-grade bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4765.

oncology
Bladder cancer biomarker screening based on non-targeted urine metabolomics

Jinkun Li,Bisheng Cheng,Hongbing Xie,Chuanchuan Zhan,Shipeng Li,Peiming Bai

DOI: https://doi.org/10.1007/s11255-021-03080-6

IF: 2.2662

2021-11-30

International Urology and Nephrology

Abstract:PurposeBladder cancer is one of the most common malignancies of the urinary system, and its screening relies heavily on invasive cystoscopy, which increases the risk of urethral injury and infection. This study aims to use non-targeted metabolomics methods to screen for metabolites that are significantly different between the urine of bladder cancer patients and cancer-free controls.MethodsIn this study, liquid chromatography–mass spectrometry was used to analyze the urine of bladder cancer patients (n = 57) and the cancer-free controls (n = 38) by non-targeted metabolomic analysis and metabolite identification.ResultsThe results showed that there were significant differences in the expression of 27 metabolites between bladder cancer patients and the cancer-free controls.ConclusionIn the multivariate statistical analysis of this study, the urinary metabolic profile data of bladder cancer patients were analyzed, and the receiver operating characteristic curve analysis showed that it is possible to perform non-invasive clinical diagnoses of bladder cancer through these candidate biomarkers.

urology & nephrology
Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS

Rui Wang,Huaixing Kang,Xu Zhang,Qing Nie,Hongling Wang,Chaojun Wang,Shujun Zhou

DOI: https://doi.org/10.1186/s12885-022-09318-5

IF: 4.638

2022-02-28

BMC Cancer

Abstract:Abstract Bladder cancer (BC) is one of the most frequent cancer in the world, and its incidence is rising worldwide, especially in developed countries. Urine metabolomics is a powerful approach to discover potential biomarkers for cancer diagnosis. In this study, we applied an ultra-performance liquid chromatography coupled to mass spectrometry (UPLC-MS) method to profile the metabolites in urine from 29 bladder cancer patients and 15 healthy controls. The differential metabolites were extracted and analyzed by univariate and multivariate analysis methods. Together, 19 metabolites were discovered as differently expressed biomarkers in the two groups, which mainly related to the pathways of phenylacetate metabolism, propanoate metabolism, fatty acid metabolism, pyruvate metabolism, arginine and proline metabolism, glycine and serine metabolism, and bile acid biosynthesis. In addition, a subset of 11 metabolites of those 19 ones were further filtered as potential biomarkers for BC diagnosis by using logistic regression model. The results revealed that the area under the curve (AUC) value, sensitivity and specificity of receiving operator characteristic (ROC) curve were 0.983, 95.3% and 100%, respectively, indicating an excellent discrimination power for BC patients from healthy controls. It was the first time to reveal the potential diagnostic markers of BC by metabolomics, and this will provide a new sight for exploring the biomarkers of the other disease in the future work.

oncology
The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery

Nicola Antonio di Meo,Francesco Lasorsa,Monica Rutigliano,Martina Milella,Matteo Ferro,Michele Battaglia,Pasquale Ditonno,Giuseppe Lucarelli

DOI: https://doi.org/10.1080/14737159.2023.2195553

2023-03-30

Expert Review of Molecular Diagnostics

Abstract:Lipidomics focuses on the in-depth analysis of lipids, which are crucial macromolecules involved in a wide range of metabolic pathways. The increased intracellular accumulation of different classes of lipids in renal cell carcinoma (RCC) and prostate cancer (PCa) cells may be caused by elevated absorption or by increased de novo lipogenesis as a consequence of lipid metabolism reprogramming. The involvement of cholesterol metabolism in cancer's aberrant pathways has also been demonstrated. This review provides an update on the most important lipidomics studies and applications in RCC and PCa, with a particular focus on how knowledge of aberrant lipid pathways may be used to identify biomarkers and novel therapeutic targets. In addition, the application of this methodologies have led to novel cancer subtypes identification and patient's risk stratification. Tracking tumor progression using specific biofluid metabolite profiles offers a huge translational opportunity for urological malignancies. Lipidomics is a promising branch of 'omics' approach and should include in next decade new standardized analysis methods and randomized clinical trials in order to reach the aim to use this high-throughput technique in patient-tailored therapy perspective.

pathology
Targeted and untargeted urinary metabolic profiling of bladder cancer

Krzysztof Ossoliński,Tomasz Ruman,Valérie Copié,Brian P Tripet,Artur Kołodziej,Aneta Płaza-Altamer,Anna Ossolińska,Tadeusz Ossoliński,Anna Nieczaj,Joanna Nizioł

DOI: https://doi.org/10.1016/j.jpba.2023.115473

2023-09-05

Abstract:Bladder cancer (BC) is frequent cancer affecting the urinary tract and is one of the most prevalent malignancies worldwide. No biomarkers that can be used for effective monitoring of therapeutic interventions for this cancer have been identified to date. This study investigated polar metabolite profiles in urine samples from 100 BC patients and 100 normal controls (NCs) using nuclear magnetic resonance (NMR) and two methods of high-resolution nanoparticle-based laser desorption/ionization mass spectrometry (LDI-MS). Five urine metabolites were identified and quantified using NMR spectroscopy to be potential indicators of bladder cancer. Twenty-five LDI-MS-detected compounds, predominantly peptides and lipids, distinguished urine samples from BC and NCs individuals. Level changes of three characteristic urine metabolites enabled BC tumor grades to be distinguished, and ten metabolites were reported to correlate with tumor stages. Receiver-Operating Characteristics analysis showed high predictive power for all three types of metabolomics data, with the area under the curve (AUC) values greater than 0.87. These findings suggest that metabolite markers identified in this study may be useful for the non-invasive detection and monitoring of bladder cancer stages and grades.
Evaluation of aliphatic acid metabolism in bladder cancer with the goal of guiding therapeutic treatment

Tianbao Song,Kaixiang He,Jinzhuo Ning,Wei Li,Tao Xu,Weimin Yu,Ting Rao,Fan Cheng

DOI: https://doi.org/10.3389/fonc.2022.930038

IF: 4.7

2022-08-18

Frontiers in Oncology

Abstract:Urothelial bladder cancer (BLCA) is a common internal malignancy with a poor prognosis. The re-programming of lipid metabolism is necessary for cancer cell growth, proliferation, angiogenesis and invasion. However, the role of aliphatic acid metabolism genes in bladder cancer patients has not been explored. The samples’ gene expression and clinicopathological data were obtained from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Univariate, multivariate, and LASSO Cox regression were used to develop a BLCA prognostic model. GSVA was used to assess function, whereas pRRophetic was used to assess chemotherapeutic drug sensitivity. The twelve-gene signature may define the tumor immune milieu, according to the risk score model. We compared the expression of aliphatic acid metabolism genes in malignant and non-cancerous tissues and chose 90 with a false discovery rate of 0.05 for The Cancer Genome Atlas cohort. The prognostic risk score model can effectively predict BLCA OS. A nomogram including age, clinical T stage, gender, grade, pathological stage, and clinical M stage was developed as an independent BLCA prognostic predictor. The halfmaximal inhibitory concentration (IC50) was used to assess chemotherapeutic medication response. Sorafenib and Pyrimethamine were used to treat patients with low risk scores more sensitively than patients with high risk scores. Immunotherapy candidates with CMS1 exhibited higher risk ratings. The aliphatic acid prognostic risk score model can assess metabolic trends. Clinical stage and molecular subtype may be used to categorize individuals using the risk score.With this new paradigm, future cancer treatment and immunotherapy may be tailored to the patient’s exact requirements.

oncology
Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry

Joanna Nizioł,Krzysztof Ossoliński,Aneta Płaza-Altamer,Artur Kołodziej,Anna Ossolińska,Tadeusz Ossoliński,Anna Nieczaj,Tomasz Ruman

DOI: https://doi.org/10.1038/s41598-023-36874-y

IF: 4.6

2023-06-17

Scientific Reports

Abstract:Bladder cancer (BC) is a common urological malignancy with a high probability of death and recurrence. Cystoscopy is used as a routine examination for diagnosis and following patient monitoring for recurrence. Repeated costly and intrusive treatments may discourage patients from having frequent follow-up screenings. Hence, exploring novel non-invasive ways to help identify recurrent and/or primary BC is critical. In this work, 200 human urine samples were profiled using ultra-high-performance liquid chromatography and ultra-high-resolution mass spectrometry (UHPLC-UHRMS) to uncover molecular markers differentiating BC from non-cancer controls (NCs). Univariate and multivariate statistical analyses with external validation identified metabolites that distinguish BC patients from NCs disease. More detailed divisions for the stage, grade, age, and gender are also discussed. Findings indicate that monitoring urine metabolites may provide a non-invasive and more straightforward diagnostic method for identifying BC and treating recurrent diseases.

multidisciplinary sciences
Unveiling Disrupted Lipid Metabolism in Benign Prostate Hyperplasia, Prostate Cancer, and Metastatic Patients: Insights from a Colombian Nested Case-Control Study

Daniel Pardo-Rodriguez,Mary Santamaría-Torres,Angela Salinas,Eliécer Jiménez-Charris,Mildrey Mosquera,Mónica P Cala,Herney Andrés García-Perdomo

DOI: https://doi.org/10.3390/cancers15225465

2023-11-18

Abstract:Prostate cancer is a significant global health concern, and its prevalence is increasing worldwide. Despite extensive research efforts, the complexity of the disease remains challenging with respect to fully understanding it. Metabolomics has emerged as a powerful approach to understanding prostate cancer by assessing comprehensive metabolite profiles in biological samples. In this study, metabolic profiles of patients with benign prostatic hyperplasia (BPH), prostate cancer (PCa), and metastatic prostate cancer (Met) were characterized using an untargeted approach that included metabolomics and lipidomics via liquid chromatography and gas chromatography coupled with high-resolution mass spectrometry. Comparative analysis among these groups revealed distinct metabolic profiles, primarily associated with lipid biosynthetic pathways, such as biosynthesis of unsaturated fatty acids, fatty acid degradation and elongation, and sphingolipid and linoleic acid metabolism. PCa patients showed lower levels of amino acids, glycerolipids, glycerophospholipids, sphingolipids, and carnitines compared to BPH patients. Compared to Met patients, PCa patients had reduced metabolites in the glycerolipid, glycerophospholipid, and sphingolipid groups, along with increased amino acids and carbohydrates. These altered metabolic profiles provide insights into the underlying pathways of prostate cancer's progression, potentially aiding the development of new diagnostic, and therapeutic strategies.
Discovering Biomarkers in Bladder Cancer by Metabolomics

Wentao Zhang,Ziwei Zhang,Yadong Guo,Longsheng Wang,Shun Mao,Junfeng Zhang,Meng‐Nan Liu,Xudong Yao

DOI: https://doi.org/10.2217/bmm-2018-0229

2018-01-01

Biomarkers in Medicine

Abstract:It has become increasingly clear that the development of cancer, a multifactorial disease, cannot be explained by a single molecule or gene mutation. As a new discipline, metabolomics focuses on the body's metabolite changes, and attempts to find differences to explain the development of cancer; it has proven to be effective and credible. Metabolic studies of bladder cancer (BCa) lag behind those of other tumors. This review systematically outlines the specific process of metabolomics and the use of metabolomics in BCa studies in recent years. We have reviewed the in vitro cell line, bladder tumor tissue and biofluid (urine, plasma and serum) studies used in metabolomics analyses of BCa. The advantages and drawbacks of the use of different samples were compared. Based on the available studies, we have further described the aberrant metabolic pathways of BCa and have suggested some metabolites that may be potential biomarkers for BCa detection.
Profiling of Urine Carbonyl Metabolic Fingerprints in Bladder Cancer Based on Ambient Ionization Mass Spectrometry

Yuze Li,Lixia Jiang,Zhenpeng Wang,Yiran Wang,Xiaohua Cao,Lingwei Meng,Jinghan Fan,Caiqiao Xiong,Zongxiu Nie

DOI: https://doi.org/10.1021/acs.analchem.2c01890

2022-07-12

Abstract:The diagnosis of bladder cancer (BC) is currently based on cystoscopy, which is invasive and expensive. Here, we describe a noninvasive profiling method for carbonyl metabolic fingerprints in BC, which is based on a desorption, separation, and ionization mass spectrometry (DSI-MS) platform with N,N-dimethylethylenediamine (DMED) as a differential labeling reagent. The DSI-MS platform avoids the interferences from intra- and/or intersamples. Additionally, the DMED derivatization increases detection sensitivity and distinguishes carboxyl, aldehyde, and ketone groups in untreated urine samples. Carbonyl metabolic fingerprints of urine from 41 BC patients and 41 controls were portrayed and 9 potential biomarkers were identified. The mechanisms of the regulations of these biomarkers have been tentatively discussed. A logistic regression (LR) machine learning algorithm was applied to discriminate BC from controls, and an accuracy of 85% was achieved. We believe that the method proposed here may pave the way toward the point-of-care diagnosis of BC in a patient-friendly manner.
Current look at the most promising proteomic and glycomic biomarkers of bladder cancer

Stefan Harsanyi,Kristina Kianickova,Jaroslav Katrlik,Lubos Danisovic,Stanislav Ziaran

DOI: https://doi.org/10.1007/s00432-024-05623-7

2024-02-21

Journal of Cancer Research and Clinical Oncology

Abstract:Bladder cancer (BC) belongs to the most frequent cancer types. The diagnostic process is still long and costly, with a high percentage of false-positive or -negative results. Due to the cost and lack of effectiveness, older methods need to be supplemented or replaced by a newer more reliable method. In this regard, proteins and glycoproteins pose high potential.

oncology
Urinary Metabolic Markers of Bladder Cancer: A Reflection of the Tumor or the Response of the Body?

Greta Petrella,Giorgia Ciufolini,Riccardo Vago,Daniel Oscar Cicero

DOI: https://doi.org/10.3390/metabo11110756

IF: 4.1

2021-10-31

Metabolites

Abstract:This work will review the metabolic information that various studies have obtained in recent years on bladder cancer, with particular attention to discovering biomarkers in urine for the diagnosis and prognosis of this disease. In principle, they would be capable of complementing cystoscopy, an invasive but nowadays irreplaceable technique or, in the best case, of replacing it. We will evaluate the degree of reproducibility that the different experiments have shown in the indication of biomarkers, and a synthesis will be attempted to obtain a consensus list that is more likely to become a guideline for clinical practice. In further analysis, we will inquire into the origin of these dysregulated metabolites in patients with bladder cancer. For this purpose, it will be helpful to compare the imbalances measured in urine with those known inside tumor cells or tissues. Although the urine analysis is sometimes considered a liquid biopsy because of its direct contact with the tumor in the bladder wall, it contains metabolites from all organs and tissues of the body, and the tumor is separated from urine by the most impermeable barrier found in mammals. The distinction between the specific and systemic responses can help understand the disease and its consequences in more depth.

biochemistry & molecular biology
Integrated Analysis of Energy Metabolism Signature-Identified Distinct Subtypes of Bladder Urothelial Carcinoma

Fan Zhang,Jiayu Liang,Dechao Feng,Shengzhuo Liu,Jiapei Wu,Yongquan Tang,Zhihong Liu,Yiping Lu,Xianding Wang,Xin Wei

DOI: https://doi.org/10.3389/fcell.2022.814735

IF: 5.5

2022-02-23

Frontiers in Cell and Developmental Biology

Abstract:Background: Bladder urothelial carcinoma (BLCA) is the most common type of bladder cancer. In this study, the correlation between the metabolic status and the outcome of patients with BLCA was evaluated using data from the Cancer Genome Atlas and Gene Expression Omnibus datasets. Methods: The clinical and transcriptomic data of patients with BLCA were downloaded from the Cancer Genome Atlas and cBioPortal datasets, and energy metabolism-related gene sets were obtained from the Molecular Signature Database. A consensus clustering algorithm was then conducted to classify the patients into two clusters. Tumor prognosis, clinicopathological features, mutations, functional analysis, ferroptosis status analysis, immune infiltration, immune checkpoint-related gene expression level, chemotherapy resistance, and tumor stem cells were analyzed between clusters. An energy metabolism-related signature was further developed and verified using data from cBioPortal datasets. Results: Two clusters (C1 and C2) were identified using a consensus clustering algorithm based on an energy metabolism-related signature. The patients with subtype C1 had more metabolism-related pathways, different ferroptosis status, higher cancer stem cell scores, higher chemotherapy resistance, and better prognosis. Subtype C2 was characterized by an increased number of advanced BLCA cases and immune-related pathways. Higher immune and stromal scores were also observed for the C2 subtype. A signature containing 16 energy metabolism-related genes was then identified, which can accurately predict the prognosis of patients with BLCA. Conclusion: We found that the energy metabolism-associated subtypes of BLCA are closely related to the immune microenvironment, immune checkpoint-related gene expression, ferroptosis status, CSCs, chemotherapy resistance, prognosis, and progression of BLCA patients. The established energy metabolism-related gene signature was able to predict survival in patients with BLCA.

cell biology,developmental biology
Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data

Yang Hao,Daixi Li,Yong Xu,Jian Ouyang,Yongkun Wang,Yuqi Zhang,Baoguo Li,Lu Xie,Guangrong Qin

DOI: https://doi.org/10.1186/s12859-019-2734-4

IF: 3.307

2019-05-01

BMC Bioinformatics

Abstract:BackgroundLipid metabolism reprogramming is a hallmark for tumor which contributes to tumorigenesis and progression, but the commonality and difference of lipid metabolism among pan-cancer is not fully investigated. Increasing evidences suggest that the alterations in tumor metabolism, including metabolite abundance and accumulation of metabolic products, lead to local immunosuppression in the tumor microenvironment. An integrated analysis of lipid metabolism in cancers from different tissues using multiple omics data may provide novel insight into the understanding of tumorigenesis and progression.ResultsThrough systematic analysis of the multiple omics data from TCGA, we found that the most-widely altered lipid metabolism pathways in pan-cancer are fatty acid metabolism, arachidonic acid metabolism, cholesterol metabolism and PPAR signaling. Gene expression profiles of fatty acid metabolism show commonalities across pan-cancer, while the alteration in cholesterol metabolism and arachidonic acid metabolism differ with tissue origin, suggesting tissue specific lipid metabolism features in different tumor types. An integrated analysis of gene expression, DNA methylation and mutations revealed factors that regulate gene expression, including the differentially methylated sites and mutations of the lipid genes, as well as mutation and differential expression of the up-stream transcription factors for the lipid metabolism pathways. Correlation analysis of the proportion of immune cells in the tumor microenvironment and the expression of lipid metabolism genes revealed immune-related differentially expressed lipid metabolic genes, indicating the potential crosstalk between lipid metabolism and immune response. Genes related to lipid metabolism and immune response that are associated with poor prognosis were discovered including HMGCS2, GPX2 and CD36, which may provide clues for tumor biomarkers or therapeutic targets.ConclusionsOur study provides an integrated analysis of lipid metabolism in pan-cancer, highlights the perturbation of key metabolism processes in tumorigenesis and clarificates the regulation mechanism of abnormal lipid metabolism and effects of lipid metabolism on tumor immune microenvironment. This study also provides new clues for biomarkers or therapeutic targets of lipid metabolism in tumors.

biochemical research methods,biotechnology & applied microbiology,mathematical & computational biology
The role of clinical metabolomics in the diagnosis of bladder cancer

Sergey A. Zamyatnin,Anton V. Malushko,Irina S. Gonchar

DOI: https://doi.org/10.17816/uroved108815

2022-10-28

Abstract:BACKGROUND: Bladder cancer is a widespread disease characterized by high cancer-specific mortality and high cost of treatment. The search for available and reliable biological markers for the early diagnosis of urothelial carcinomas is an urgent task of oncourology. One of the promising ways to improve the efficiency of bladder cancer diagnostics is the use of the possibility of the clinical metabolomics. AIM: Was to study the possibility of assessing the content of various amino acids and their metabolites in blood serum for the diagnosis of bladder cancer. MATERIALS AND METHODS: Serum concentrations of 28 amino acids and their metabolites were studied in 18 patients with urothelial cancer and 20 representatives of the control group without an oncological history. History taking, routine oncological screening, and blood sampling for laboratory tests were performed. RESULTS: Four metabolomes (glycine, phenylalanine, asparagine, and threonine) were identified, the blood serum concentration of which significantly changes in patients with urothelial cancer. These metabolomes can be considered as potential biomarkers of urothelial cancer. CONCLUSIONS: The study of the serum content of these four amino acids seems to be the most promising for the isolation of a potential biomarker of urothelial cancer.
Cancer Focus Lipid metabolism and cancer

Xueli Bian,Rui Liu,Ying Meng,Dongming Xing,Daqian Xu,Zhimin Lu

DOI: https://doi.org/10.1084/jem.20201606

2021-01-01

Abstract:Dysregulation in lipid metabolism is among the most prominent metabolic alterations in cancer. Cancer cells harness lipid metabolism to obtain energy, components for biological membranes, and signaling molecules needed for proliferation, survival, invasion, metastasis, and response to the tumor microenvironment impact and cancer therapy. Here, we summarize and discuss current knowledge about the advances made in understanding the regulation of lipid metabolism in cancer cells and introduce different approaches that have been clinically used to disrupt lipid metabolism in cancer therapy.

Lipid Metabolism Profiling and Bladder Cancer

Characterization of the Lipid Metabolism in Bladder Cancer to Guide Clinical Therapy

Integrative Analysis of Plasma Metabolomics and Proteomics Reveals the Metabolic Landscape of Breast Cancer

Metabolomic profiling of human bladder tissue extracts

In Silico Establishment and Validation of Novel Lipid Metabolism-Related Gene Signature in Bladder Cancer

Abstract 4765: Tumor, serum and plasma metabolome in patients with high-grade bladder cancer

Bladder cancer biomarker screening based on non-targeted urine metabolomics

Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS

The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery

Targeted and untargeted urinary metabolic profiling of bladder cancer

Evaluation of aliphatic acid metabolism in bladder cancer with the goal of guiding therapeutic treatment

Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry

Unveiling Disrupted Lipid Metabolism in Benign Prostate Hyperplasia, Prostate Cancer, and Metastatic Patients: Insights from a Colombian Nested Case-Control Study

Discovering Biomarkers in Bladder Cancer by Metabolomics

Profiling of Urine Carbonyl Metabolic Fingerprints in Bladder Cancer Based on Ambient Ionization Mass Spectrometry

Current look at the most promising proteomic and glycomic biomarkers of bladder cancer

Urinary Metabolic Markers of Bladder Cancer: A Reflection of the Tumor or the Response of the Body?

Integrated Analysis of Energy Metabolism Signature-Identified Distinct Subtypes of Bladder Urothelial Carcinoma

Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data

The role of clinical metabolomics in the diagnosis of bladder cancer

Cancer Focus Lipid metabolism and cancer